Alcohol Use Disorder Risk and Your Genetics

Reviewed by the ExomeDNA Science Team

This page contains general information only. For personal health decisions, consult a qualified clinician.

Alcohol use disorder (AUD) is a chronic condition defined by the development of physical dependence on alcohol — including tolerance and withdrawal symptoms when drinking stops — and it affects an estimated 29 million adults in the United States. Genetic variation across at least seven well-characterized genes shapes an individual's metabolic processing of alcohol, dopamine reward signaling, liver glucose regulation, zinc transport, FGF21-mediated craving control, and cochlear vulnerability to alcohol-related damage. Below: what those genes do, what the research shows, and how to act on your ExomeDNA result.

What is alcohol use disorder?

Alcohol use disorder sits at the severe end of a spectrum of alcohol-related problems. What separates AUD from hazardous or harmful drinking is physical dependence: the body adapts to the chronic presence of alcohol at the neurochemical level, so that removing it triggers a physiological withdrawal syndrome. Withdrawal symptoms range from anxiety and insomnia at the mild end to tremors, hallucinations, seizures, and — in the most severe presentation — delirium tremens, a potentially life-threatening state requiring emergency medical management.

Tolerance is the other hallmark. Over time, the same quantity of alcohol produces a diminishing subjective effect, driving escalating consumption to achieve the same relief or pleasure. This escalation is partly mediated by neuroadaptation in dopamine, GABA, and glutamate systems — changes that genetic variation influences from the outset.

AUD is a medical condition, not a character defect. Its heritability is estimated at 40–60%, placing it firmly in the range of conditions like type 2 diabetes and hypertension where genes contribute meaningfully alongside environment, social context, and behavior.

The genetics behind alcohol use disorder risk

Seven authorized genes are relevant to this ExomeDNA result. Each affects a different biological pathway.

ADH1B (alcohol dehydrogenase 1B) encodes the primary enzyme that converts ethanol to acetaldehyde in the liver. The rs1229984 variant dramatically speeds this conversion, causing a rapid acetaldehyde accumulation that produces flushing, nausea, and cardiovascular discomfort — a built-in aversive response that strongly discourages heavy drinking. Carriers of the protective allele have substantially lower rates of AUD. People without it face no such biological brake on alcohol metabolism.

DRD2 (dopamine D2 receptor) is the most mechanistically important gene for understanding why AUD is hard to stop once established. The dopamine D2 receptor governs the brain's ability to register pleasure and reward from natural activities — food, social connection, exercise, creative work. Chronic heavy alcohol use causes progressive D2 receptor downregulation: the brain produces fewer receptors as a compensatory response to the dopamine flooding driven by alcohol. The consequence is withdrawal dysphoria — a sustained inability to feel pleasure from anything other than alcohol during early abstinence. DRD2 variants determine baseline receptor density, which sets the starting point for this downregulation process and influences how quickly receptor numbers recover during sustained sobriety. Variants associated with lower baseline D2 density confer greater vulnerability to reward system collapse in AUD.

KLB (beta-Klotho) encodes the obligate co-receptor for fibroblast growth factor 21 (FGF21) signaling. FGF21 is a liver-derived hormone with a well-documented role in alcohol appetite regulation: it rises after alcohol exposure and signals the brain to reduce further consumption. This is a natural homeostatic brake. People with KLB variants that impair FGF21 co-receptor sensitivity have a diminished version of this brake. During withdrawal, when alcohol is removed and FGF21 levels shift, impaired KLB-mediated signaling may produce more intense craving because the liver's "stop drinking" signal was already operating below full strength. This pathway has become a target of early-stage pharmacological interest.

FTO (fat mass and obesity-associated gene) is best known for its role in energy homeostasis and body weight regulation, but its relevance in AUD is metabolic. Alcohol delivers approximately 7 kilocalories per gram — comparable to fat — with no micronutrient value. Heavy drinking therefore adds substantial caloric load on top of disrupted appetite regulation. FTO variants affecting energy sensing interact with alcohol's caloric contribution, influencing body weight trajectory and metabolic syndrome risk in people with significant AUD history.

GCKR (glucokinase regulatory protein) regulates glucose sensing in the liver. The liver is the primary site of alcohol metabolism, and chronic heavy drinking disrupts hepatic glucose regulation through multiple mechanisms including glycogen depletion and impaired gluconeogenesis. GCKR variants affecting how the liver senses and responds to glucose influence the severity of metabolic complications — including hypoglycemia, dyslipidemia, and non-alcoholic fatty liver progression — in people with AUD.

SLC39A8 (zinc transporter ZIP8) transports zinc across cell membranes, and this has a specific relevance in AUD that is often overlooked. Chronic heavy alcohol consumption causes progressive zinc depletion through multiple routes: reduced dietary intake, impaired intestinal absorption, and increased urinary zinc excretion. Zinc is a critical modulator of GABA-A receptor function — zinc ions normally bind to GABA-A receptors and inhibit their activity, fine-tuning the inhibitory tone of the central nervous system. When zinc is depleted, this inhibitory modulation is reduced, which may contribute to the excitatory imbalance underlying alcohol withdrawal seizures. SLC39A8 variants affecting zinc transport efficiency influence how quickly zinc depletion accumulates during heavy drinking and how readily zinc levels recover during abstinence.

TMPRSS5 (transmembrane serine protease 5) is expressed in the cochlea — specifically in the spiral ganglion neurons and hair cells of the inner ear — and is implicated in normal hearing function. Chronic alcohol use is an established cause of auditory system damage through metabolic and oxidative toxicity to cochlear tissue. The link between AUD and hearing loss, including high-frequency hearing decline and tinnitus, is documented but underrecognized as an AUD complication. TMPRSS5 variation is associated with audiometric traits in genome-wide data, suggesting that genetic differences in cochlear biology may influence individual vulnerability to this specific AUD-related complication.

What the research says

Research base: Robust.

The genetic architecture of alcohol use disorder and alcoholism-spectrum phenotypes has been studied in some of the largest genetic cohorts ever assembled.

The primary source supporting this ExomeDNA result is a 2024 study by Verma and colleagues (PMID 39024449) examining the genetic architecture of 2,068 traits across the VA Million Veteran Program — one of the largest and most ancestrally diverse biobank studies ever conducted. The scale of this work — over one million participants with linked electronic health records — provides substantially greater statistical power to detect genetic signals for AUD-related phenotypes than earlier, smaller studies, and the ancestral diversity improves the generalizability of findings beyond European-ancestry cohorts.

The biological mechanisms for several of the genes listed above — particularly ADH1B, DRD2, and KLB — have been validated across independent cohorts and multiple phenotypic approaches including both case-control designs and continuous alcohol consumption measures. The TMPRSS5 hearing connection represents a more recent and mechanistically emerging line of evidence, appropriately weighted as a plausible complication pathway rather than a primary dependence mechanism.

How alcohol use disorder affects you

The effects of AUD operate across biological, neurological, metabolic, and systemic domains simultaneously.

Neurologically, D2 receptor downregulation is among the most consequential changes. Brain imaging studies show that those with AUD have measurably reduced D2 receptor availability in the striatum compared to controls, and that this deficit persists for weeks to months into early recovery. During this window, the inability to experience normal reward from everyday activities — the withdrawal dysphoria described above — is a major driver of relapse. Recovery of D2 receptor density is gradual and is meaningfully supported by activities that engage the dopamine reward system through natural means.

Metabolically, the liver bears the primary burden of alcohol processing. Fatty liver disease, alcoholic hepatitis, and cirrhosis represent the progression of liver injury in sustained heavy drinking. GCKR and FTO variants interact with this metabolic load by influencing how the liver and adipose tissue manage the caloric and glucose disruption that alcohol imposes.

Nutritionally, zinc and B-vitamin depletion are well-documented in AUD. Zinc deficiency (influenced by SLC39A8 transport efficiency) impairs immune function, wound healing, and as noted above, GABA-A receptor modulation. Thiamine (vitamin B1) depletion leads to Wernicke's encephalopathy in severe cases — a medical emergency.

Audiologically, hearing loss and tinnitus are more prevalent in individuals with AUD than the general population, a complication frequently attributed to alcohol's cochlear toxicity. TMPRSS5 expression in spiral ganglion neurons positions this gene as a plausible modifier of individual cochlear vulnerability, though this remains an area of active investigation rather than a fully established clinical predictor.

Working with your alcohol use disorder result

Your ExomeDNA result reflects polygenic risk based on population-level genetic association data. This is not a clinical finding and does not predict whether AUD will occur. What it does provide is information about biological pathways that may be relevant to your risk profile. Use it in the context of your overall health history and in consultation with a clinician.

If your result indicates elevated polygenic risk, the following numbered steps are evidence-grounded responses:

1. Medical supervision for any alcohol withdrawal. If you currently drink heavily and are considering stopping, do not stop abruptly without medical evaluation. Alcohol withdrawal seizures can be life-threatening. Seek medical assessment — supervised withdrawal (detoxification) with appropriate pharmacological support (typically benzodiazepines) is the evidence-based standard.

2. Ask about evidence-based pharmacotherapy. Naltrexone (an opioid receptor antagonist) reduces alcohol craving and relapse rates by attenuating the dopamine reward signal that drives continued drinking — directly relevant to the DRD2 pathway. Acamprosate supports GABA/glutamate balance during early abstinence. Both are FDA-approved for AUD treatment and are significantly underused. Discuss these options with a prescribing clinician.

3. Address zinc status during recovery. Zinc depletion is common in AUD history. A clinician can check serum zinc and recommend supplementation if indicated. Restoring zinc is particularly relevant given SLC39A8's role in zinc transport and the GABA-A modulating function of zinc in neurological recovery.

4. Schedule an audiological evaluation. For those with a significant history of heavy alcohol use, audiometry (a hearing test) is a reasonable preventive screen. Alcohol-related hearing loss is often high-frequency and progressive; early identification allows for monitoring and management.

5. Prioritize dopamine-restoring activities during recovery. Exercise, in particular, has documented effects on dopamine receptor density and neuroplasticity. Social engagement, creative work, and novelty-seeking activities that don't involve substance use all activate the dopamine reward system and support D2 receptor recovery over time. This is mechanistically grounded, not generic wellness advice.

6. Support liver and FGF21 function. Minimizing added sugars and fructose, maintaining a healthy body weight, and avoiding additional hepatotoxic substances support liver health and the FGF21 signaling axis that naturally helps regulate alcohol appetite via the KLB receptor.

Related traits and genes

Alcohol use disorder risk shares genetic architecture with several related traits in the ExomeDNA database. Alcohol-related disorders (TRAIT_070872) is the broader phenotypic category that includes hazardous use, alcohol-related liver disease, and social complications of drinking alongside the physical dependence component; the two pages share ADH1B, DRD2, FTO, GCKR, KLB, and SLC39A8, but this page's focus on physical dependence and withdrawal adds the TMPRSS5 ototoxicity angle. Alcohol consumption (drinks per week) reflects habitual intake levels independent of the disorder label, shaped by overlapping but distinct genetic pathways.

Beyond alcohol, several genes here connect to metabolic risk traits. FTO variants influence body mass index and obesity risk independently of alcohol behavior. GCKR variants are associated with type 2 diabetes risk and fasting triglycerides through the same hepatic glucose sensing mechanisms relevant to AUD metabolic complications. DRD2 connects to nicotine dependence and opioid use disorder risk through shared dopamine reward circuitry — a reason why polysubstance use and co-occurring addictions are common.

The ADH1B gene page covers alcohol dehydrogenase enzyme variants in greater depth, including the population-level distribution of the protective rs1229984 allele and its relationship to flush response phenotypes.

Frequently asked questions

References: Verma A et al. (2024). Diversity and scale: Genetic architecture of 2,068 traits in the VA Million Veteran Program. PMID 39024449.

ExomeDNA genetic results are for wellness and educational purposes only. Consult a clinician for personalized health guidance.